Team

Our Team

HLS Therapeutics is led by a team of seasoned executives. Prior to founding HLS, our proven management team led the turnaround of Biovail Pharmaceuticals through its restructuring and ultimate merger with Valeant International.

EXECUTIVE TEAM

Executive Chairman of the Board – Bill Wells, BA, MBA

Co-Founder of HLS, Former Chief Executive Officer of Biovail Corporation Canada’s largest publicly traded pharmaceutical company.

Mr. Wells is a seasoned business executive with extensive experience managing complex global businesses. He has been involved in three successful turnaround efforts of major public companies and led the turnaround of Biovail, first as Lead Director of the board and then as CEO.

Chief Executive Officer – Greg Gubitz, BA, LLB

Co-Founder of HLS, Former Senior Vice President, Corporate Development and General Counsel of Biovail Corporation.

Mr. Gubitz is a seasoned executive and business lawyer, with significant transaction, investment & operating experience. As General Counsel of Biovail, he was responsible for mergers & acquisitions and for worldwide legal operations.

President and Chief Operating Officer – Gilbert Godin, BEng, MBA

Co-Founder of HLS, Former Executive VP and COO of Biovail Corporation.

More recently, Mr. Godin, built the team that successfully took the first Duchesnay approved product to market. He has held executive leadership positions in Canada, Europe and in the U.S., for MDS, Schering-Plough, and L’Oreal.

Chief Financial Officer – Tim Hendrickson, MBA

Former executive with Cubist Pharmaceuticals through its acquisition by Merck & Co  in early 2015.

Mr. Hendrickson is a financial executive with over 15 years of experience at companies such as Procter & Gamble, P&G Pharmaceuticals and Warner Chilcott. He has held leadership roles in finance & accounting, forecasting & financial analysis, business development & planning, customer service, distribution and operations.

Head of Corporate Strategy and Business Development – Hemanth Varghese, PhD

Dr. Varghese is a Pharmaceutical Executive with over 14 years of corporate development and operations experience. He has recently held senior executive positions at Valeant and Endo in Business Development and in Operations, prior to which he was VP of Business Development for Biovail. During those tenures, he worked closely with executive teams to drive growth and shareholder value through expansion into new markets and geographies.

General Counsel – Ryan C. Lennox BA, JD

Ryan C. Lennox is a former Senior Counsel at Amgen Inc., where he was responsible for all of the legal affairs of the company’s Canadian affiliate. He also took on increasing responsibility, including managing the legal team and affairs of Amgen’s Intercontinental Region, comprised of Canada, Latin America, Turkey, Middle East and Africa.

Mr. Lennox is called to the bar in both California and Ontario. Prior to joining Amgen, Mr. Lennox practiced corporate law at two international law firms, in San Diego, California and Toronto, Ontario, where he advised a wide variety of clients on corporate finance, M&A, private equity, venture capital and other kinds of transactions.

Chief Commercial Officer – Sanjiv Sharma, MBA

Former SVP Worldwide Commercial & Country Head-US for NicOx, and VP Commercial for Duchesnay USA.

Mr. Sharma has been a pharmaceutical executive for over 25 years. He is equally experienced in large, mid-size and startups in North America and Asia, with national and global responsibility for General Management, Sales & Marketing, Market Access & Business Development. Mr. Sharma oversaw strategic marketing & planning for Biovail and spent 15 years with Sanofi-Aventis in Sales and Marketing leadership roles in Canada and the U.S.

VP Scientific Affairs – Jason A. Gross, PharmD

Dr. Gross spent five years at the National Institutes of Health (NIH) and the Food & Drug Administration (FDA).

Dr. Gross is a pharmaceutical executive with more than 20 years of experience focused on clinical development, regulatory affairs, manufacturing and quality assurance. He is a former VP of Scientific and Medical Affairs at Cipher Pharmaceutics, MDS Capital, and Zenith Goldline.

VP Integration Management – Carmel Daughtery, PMP

Former Vice President, Project Management Office at Biovail Corporation.

Mrs. Daughtery is a multi-disciplinary life science executive with 25 years of experience focused in the pharmaceutical and medical device industry. She has a diverse background encompassing alliance management, project management, technical operations and product and process development, gained in small and Fortune Global 500 companies.

BOARD OF DIRECTORS

Executive Chairman of the Board – Bill Wells, BA, MBA

Co-Founder of HLS, Former Chief Executive Officer of Biovail Corporation, Canada’s largest publicly traded pharmaceutical company.

Mr Wells is a seasoned business executive with extensive experience managing complex global businesses. He has been involved in three successful turnaround efforts of major public companies and led the turnaround of Biovail, first as Lead Director of the board and then as CEO.

Chief Executive Officer – Greg Gubitz, BA, LLB

Co-Founder of HLS, Former Senior Vice President, Corporate Development and General Counsel of Biovail Corporation.

Mr. Gubitz is a seasoned executive and business lawyer, with significant transaction, investment & operating experience. As General Counsel of Biovail, he was responsible for mergers & acquisitions and for worldwide legal operations.

Director, Independent – J. Spencer Lanthier

Former chief executive officer of KPMG Canada, is a member of the Order of Canada and has served on various boards including TMX Group and The Bank of Canada.

Mr. Lanthier served as Lead Director of Valeant Pharmaceuticals International, Inc., has been Director of Biovail Corporation and was Corporate Director of Ontario Genomics Institute. He has been recognized in the Financial Post’s Top 200 Chief Executive Officer listings. Mr. Lanthier was educated at McGill University and holds an Honorary Doctor of Law Degree from the University of Toronto.

Director, Independent – Yvon Bastien

Former chief executive officer of Sanofi Canada and currently serves on the boards of Helix BioPharma and Telesta Therapeutics.

Mr. Bastien has more than 25 years of very successful experience in the pharmaceutical industry, where he occupied senior positions both at the national and international levels. He has held executive positions at Laboratoire Debat in Paris, IMS Canada in Montreal, and Eli Lilly in Montreal.

Director, Independent – Daniel Tassé

Chairman and CEO of Alcresta Therapeutics and currently serves on the boards of REGENXBIO Inc. and Bellerophon Therapeutics and formerly served as Chairman and CEO of Ikaria, Inc. until its acquisition by Mallinckrodt Pharmaceuticals in 2015.

Mr. Tassé is a seasoned health care executive who has built and led pharmaceutical and drug-device businesses with global footprints. Prior to joining, Mr Tassé served as General Manager of the Pharmaceuticals and Technologies Business Unit of Baxter International and earlier in his career, held senior management positions at GlaxoSmithKline (GSK).

Director, Independent – Don DeGolyer

Founder & CEO and director of the Board of Vertice Pharma.

Mr. DeGolyer has over 30 years of pharmaceutical experience building and leading top tier performing organizations. He was previously the Chief Operating Officer of Endo Pharmaceuticals where he built one of the fastest growing Specialty Pharmaceuticals businesses. He also served as President & CEO of Sandoz North America as it became the second largest generics company in the world. Mr. DeGolyer began his career at Pfizer, Johnson & Johnson and then Novartis, progressing through various roles of increasing responsibility.

Director, Independent – Rodney Hill

Chief Risk Officer of Ontario Municipal Employees Retirement System Administration Corporation (“OMERS”).

Mr. Hill has more than 28 years of experience in business management, risk management, finance and accounting. Mr. Hill joined OMERS in 2011 as EVP & Chief Auditor and moved to his current position in 2015. Prior to joining OMERS, Mr. Hill spent 22 years working at PricewaterhouseCoopers and the last 10 years as a Partner specializing in auditing complex public and private companies in a variety of sectors including pharmaceuticals.

Brand names you know. Safe and effective results you trust.